

Figure 1. Representative computed tomography images at baseline (A) and after 2 cycles of selpercatinib (B) showing decrease in pulmonary disease burden, which was maintained after 9 cycles at dose level -1 (18 total cycles) (C) and approximately 10 cycles at dose level -2 (28 total cycles) (D)

